Medicine and Dentistry
Adjuvant
16%
Adjuvant Endocrine Therapy
100%
Adverse Event
100%
Aromatase Inhibitor
100%
Breast Cancer
100%
Cancer
33%
Cardiovascular System
33%
Cerebrovascular Disease
16%
Endometrial Cancer
16%
Fracture
50%
Hormone Receptor
16%
Linear Regression Analysis
16%
Monotherapy
16%
Odds Ratio
33%
Phlebothrombosis
16%
Postmenopause
100%
Recurrent Disease
16%
Sequential Analysis
16%
Tamoxifen
83%
Keyphrases
Adjuvant Endocrine Therapy
100%
Adverse Events
100%
Aromatase Inhibitors
100%
Bone Fracture
50%
Breast Cancer
16%
Cardiovascular Events
16%
Cardiovascular Risk
16%
Cerebrovascular Disease
16%
Early Breast Cancer
100%
Endometrial Cancer
16%
Hormone Receptor-positive Breast Cancer
16%
Improved Outcomes
16%
Monotherapy
16%
Odds Ratio
33%
Postmenopausal Women
100%
Secondary Malignancy
33%
Toxicity Profile
33%
Treatment Discontinuation
16%
Venous Thrombosis
16%
Weighted Linear Regression
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
16%
Adverse Event
100%
Aromatase Inhibitor
100%
Breast Cancer
100%
Cerebrovascular Disease
16%
Endocrine Therapy
100%
Endometrium Cancer
16%
Fracture
50%
Hormone Receptor
16%
Monotherapy
16%
Recurrent Disease
16%
Tamoxifen
83%
Vein Thrombosis
16%